Meyka Pro banner
Tatva Chintan Pharma Chem Limited

Tatva Chintan Pharma Chem Limited (NSE: TATVA.NS) AI-Powered Stock Analysis

See how Tatva Chintan Pharma Chem Limited scores across key metrics like financial growth, valuation, and market position on the NSE, using AI-driven evaluation.

TATVA.NSNSE
Basic MaterialsChemicals - Specialty
1722.40
21.60(1.27%)
Indian Market opens in 22h 30m

Tatva Chintan Pharma Chem Limited (NSE: TATVA.NS) AI-Powered Stock Analysis

See how Tatva Chintan Pharma Chem Limited scores across key metrics like financial growth, valuation, and market position on the NSE, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Tatva Chintan Pharma Chem Limited (NSE: TATVA.NS) Stock Overall Grade

Tatva Chintan Pharma Chem Limited's grade for its NSE listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Tatva Chintan Pharma Chem Limited's overall NSE stock rating.

Forecast

B+

Score

78/100

Financial Growth

B

Score

60/100

Fundamental Growth

C+

Score

51/100

Key Ratios

B

Score

62/100

Sector Comparison

B+

Score

70/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

97/100

Analyst Consensus

C+

Score

50/100

Tatva Chintan Pharma Chem Limited (NSE: TATVA.NS) AI-Powered Stock Analysis

On the NSE, TATVA.NS demonstrates Good performance with an overall Forecast Score of 78/100 (B+), reflecting high confidence in its potential. Financial Growth (60/100, B) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (62/100, B) and Sector Comparison (70/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NSE-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests Moderate divergence in outlook.

(NSE: TATVA.NS) Component Analysis Explained

Understand the key factors behind each Tatva Chintan Pharma Chem Limited (NSE: TATVA.NS) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions